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PARP inhibitors (PARPi) cause synthetic lethality in BRCA-deficient tumors. Whether specific vulnerabilities to
PARPi exist beyond BRCAmutations and related defects in homology-directed repair (HDR) is not well under-
stood. Here, we identify the ubiquitin E3 ligase TRIP12 as negative regulator of PARPi sensitivity. We show that
TRIP12 controls steady-state PARP1 levels and limits PARPi-induced cytotoxic PARP1 trapping. Upon loss of
TRIP12, elevated PARPi-induced PARP1 trapping causes increased DNA replication stress, DNA damage, cell
cycle arrest, and cell death.Mechanistically, we demonstrate that TRIP12 binds PARP1 via a central PAR-bind-
ing WWE domain and, using its carboxy-terminal HECT domain, catalyzes polyubiquitylation of PARP1, trig-
gering proteasomal degradation and preventing supra-physiological PARP1 accumulation. Further, in cohorts
of breast and ovarian cancer patients, PARP1 abundance is negatively correlated with TRIP12 expression. We
thus propose TRIP12 as regulator of PARP1 stability and PARPi-induced PARP trapping, with potential impli-
cations for PARPi sensitivity and resistance.
INTRODUCTION
Poly(ADP-ribose) polymerase 1 (PARP1) is an abundant chro-
matin-associated enzyme, whose activity is strongly induced in
response to genotoxic stress (Gibson and Kraus, 2012; Ray
Chaudhuri and Nussenzweig, 2017; Teloni and Altmeyer, 2016).
PARP1 has affinity for DNA single- and double-strand breaks
(DSBs), for stalled and reversed replication forks, and for a range
of atypical DNA secondary structures (Alemasova and Lavrik,
2019; Neelsen and Lopes, 2015). UponDNAbinding and allosteric
activation, PARP1 uses the energy carrier nicotinamide adenine
dinucleotide (NAD+) as substrate to generate poly(ADP-ribose)
(PAR) chains (Gupte et al., 2017; Eustermann et al., 2015; Hottiger,
2015). PAR formation is important for the timely recruitment of
PAR-binding repair factors and for rearranging the local chromatin
structure in response to DNA damage and it induces liquid-liquid
phase separation of intrinsically disordered PAR-binding proteins
at chromosome break sites (Altmeyer et al., 2015; Dantuma and
van Attikum, 2016; Pellegrino and Altmeyer, 2016). PAR signaling
thus promotes DNA repair reactions and helps maintain genome
stability.When genotoxic stress is too severe, however, sustained
PARylation can deplete the cellular NAD+ pool and cause a PAR-
dependent type of cell death known as PARthanatos (Tang et al.,
2019; Wang et al., 2016; Yu et al., 2002).
While PARP inhibitors (PARPi) protect cells fromPARP1-medi-
atedNAD+depletion, their clinical use is primarily associatedwith
causing synthetic lethality in BRCA1/2-deficient tumors (Lord
and Ashworth, 2017; O’Connor, 2015). The tumor suppressors
BRCA1 and BRCA2 are critical components of the homology-
directed repair (HDR) pathway, which promotes error-free repair
of DNA double-strand breaks (DSBs) and emerges as an impor-
tant contributor to replication fork stability (Chen et al., 2018). In a
fraction of heritable and sporadic breast and ovarian cancers
BRCA1/2 function is lost, and this situation generates a cancer-
specific vulnerability to PARPi (Lord and Ashworth, 2017; O’Con-
nor, 2015). Based on the promising pre-clinical and clinical re-
sults inBRCA-deficient contexts, current efforts aimat identifying
signatures of HDR dysfunction, so that PARPi therapies could be
used in HDR-defective settings and potentially beyond BRCA
mutations (Davies et al., 2017; Lord and Ashworth, 2016).
Vulnerabilities to PARPi may, however, also exist in HDR-pro-
ficient cancer cells. In fact, by blocking access of NAD+ to the
catalytic site, PARPi lock PARP1 in an inactive cytotoxic confor-
mation, a situation generally referred to as PARP trapping (Murai
et al., 2012; Pommier et al., 2016). Consistent with PARP trap-
ping being an important cause of PARPi toxicity in BRCA-profi-
cient cells, loss of PARP1 rescues them from PARPi-induced
genotoxic stress and cell death (Michelena et al., 2018; Murai
et al., 2012). We therefore reasoned that when PARPi are applied
in conditions of BRCA1/2 and HDR proficiency, it is neither the
impaired PARP1 function nor the inability to produce PAR, but
rather the inactivated trapped PARP1 itself, which becomes
detrimental for cell survival. However, in BRCA-deficient condi-
tions, the response to PARPi is not uniform, and desired
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Figure 1. The HECT-Type Ubiquitin Ligase TRIP12 Controls PARP1 Abundance
(A) Schematic representation of WWE domain-containing ubiquitin E3 ligases. HECT, homologous to the E6-AP carboxyl terminus; RING, really interesting new
gene.
(B) Multiple sequence alignment of WWE domains present in ubiquitin E3 ligases. While RNF146, HUWE1, and TRIP12 each contain a single WWE domain,
DELTEX1, DELTEX2, and DELTEX4 each contain a tandemWWE domain. The tryptophan and glutamate residues typical of the WWE domain are marked in red.
(C) HeLa Kyoto PARP1-LAP cells expressing GFP-PARP1 from its natural promoter were transfected with negative control siRNA or with siRNAs against WWE-
containing ubiquitin E3 ligases. Nuclear GFP-PARP1 levels were analyzed 72 h after siRNA transfection by high-content microscopy. Pooled results from two
independent siRNAs against each target protein are shown. Mean (solid line) and standard deviation (SD) from the mean (dashed lines) are indicated. Repre-
sentative single cell images are shown below. Scale bar, 10 mm.
(D) Western blot analysis of GFP-PARP1 levels in HeLa Kyoto PARP1-LAP cells transfected with negative control siRNA or siRNA against TRIP12. GFP-PARP1
and poly(ADP-ribose) band intensities were quantified in Fiji and the fold change is indicated below.
(legend continued on next page)




responses are only observed in a fraction of patients with germ-
line BRCA1/2 mutations (Faraoni and Graziani, 2018). For
instance, the overall response rate in BRCA-mutated ovarian
cancer is <50% in multiple phase II clinical trials (Boussios
et al., 2019), warranting identification of additional biomarkers
for PARPi responses. As regulators of PARP1 may determine
PARPi-induced PARP1 trapping and PARPi efficiency, uncover-
ing such regulators and characterizing their molecular and
cellular functions might help to better stratify cancer patients
for PARPi therapy and pave theway for patients without a BRCA-
ness signature to possibly benefit from PARPi.
RESULTS
TRIP12 Counteracts PARP1 Abundance
To identify regulators of PARP1 and PARPi sensitivity, we focused
on putative PAR-binding components of the ubiquitin-protea-
some system. In human cells, only six ubiquitin E3 enzymes are
known to combine within their structure a high-affinity PAR-bind-
ing domain of the WWE type, which recognizes iso-ADP-ribose,
with a ubiquitin E3 ligase domain of either the homologous to
the E6-AP carboxyl terminus (HECT) or really interesting new
gene (RING) type (Figure 1A). Sequence alignment of the WWE
domains confirms the presence of the eponymous tryptophan
and glutamate residues in all six proteins (Figure 1B). Using a pre-
viously established high-content cell imaging system to assess
multiple parameters of PARPi sensitivity and resistance (Michel-
ena et al., 2018), we followed anRNAi approachwith two indepen-
dent small interfering RNAs (siRNAs) against each target,
measuring nuclear PARP1 intensities in transgenic HeLa Kyoto
cells stably expressing EGFP-tagged PARP1 from its natural pro-
moter (Aleksandrov et al., 2018) as readout. This revealed
elevated PARP1 levels particularly upon downregulation of the
HECT domain ubiquitin E3 ligase TRIP12 (Figure 1C). TRIP12, a
primarily nuclear protein of around 200 kDa, which is also known
as ULF, is altered in around 4%of cancer patients, with a somatic
mutation frequency of 2.8% according to The Cancer Genome
Atlas (TCGA) PanCancer Atlas data on cBioPortal (Cerami et al.,
2012; Gao et al., 2013). In support of our initial observation, indi-
vidual validation experiments by both high-content microscopy
and western blot confirmed elevated PARP1 abundance upon
TRIP12 depletion, while steady-state PAR levels were only very
mildly increased (Figures 1D and S1A). The cell cycle distribution
remained largely unaffected under these conditions (Figure S1B).
Similar results were obtained in human bone osteosarcoma
epithelial cells (U-2OS) cells (Figures S1C andS1D) andwith three
independent siRNAs against TRIP12 (Figure S1E). Elevated
PARP1 levels upon TRIP12 depletion were also observed in
hTERT-immortalized RPE-1 cells (Figure S1F), and in the triple-
negative breast cancer cell line HCC1143 (Figure S1G). When
the TRIP12 knockdown was enhanced through two consecutive
rounds of siRNA transfection, the effect on PARP1 abundance
was even more pronounced (Figure S1H). PARP1 mRNA levels,
on the other hand, were only very mildly affected by TRIP12 loss
(Figure S1I), suggesting that TRIP12 regulates PARP1 mainly at
the protein rather than the gene expression level. In line with our
knockdown experiments, overexpression of GFP-TRIP12
reduced ectopically expressed PARP1 in PARP1 knockout (KO)
cells (Figures 1E and S1J), and GFP-TRIP12 expression was
inversely correlated with nuclear abundance of endogenous
PARP1 (Figures 1F and S1K). Collectively, these results reveal
that nuclear PARP1 levels are negatively regulated by the ubiquitin
ligase TRIP12.
TRIP12 Limits PARylation and Affects Outcomes of PAR
Signaling
When we used short-term chemical inhibition of the PAR-de-
grading enzyme PARG to detect endogenous PAR formation
as performed previously (Hanzlikova et al., 2018), we observed
a moderate increase in PAR levels after TRIP12 depletion (Fig-
ures S2A and S2B). Moreover, when we induced DNA damage,
PARP1 accumulation at sites of laser micro irradiation was more
sustained (Figure 2A), and PAR formation at the laser stripe was
more pronounced in absence of TRIP12 (Figure 2B). Consistent
with elevated PAR formation at DNA break sites, recruitment of
the PAR-binding protein XRCC1 to laser damage was enhanced
upon TRIP12 depletion (Figure 2C). Similarly, XRCC1 chromatin
association in response to H2O2-induced oxidative DNA damage
was increased in TRIP12-depleted cells (Figure S2C). On the
other hand, MDC1 recruitment, which is dependent on ataxia tel-
angiectasia-mutated (ATM) activation and gH2AX generation
rather than PAR, was not facilitated by TRIP12 depletion (Fig-
ure 2D). Collectively, these findings indicate that TRIP12 con-
strains PAR formation and PAR-dependent protein recruitment
to sites of DNA damage.
As hyper-activation of PARP1 under severe conditions of gen-
otoxic stress can lead to PARthanatos, we aimed to test whether
loss of TRIP12 would sensitize cells to PARP1-dependent cell
death. Using AIF (apoptosis-inducing factor) translocation from
the mitochondria to the nucleus as hallmark of PARthanatos
upon exposure to oxidative damage in conjunction with inhibition
of the NAD+ salvage pathway, we observed elevated nuclear AIF
localization and condensed nuclei in TRIP12-depleted cells (Fig-
ures S2D and S2E). Inhibition of PARP activity under these condi-
tions rescued the observed AIF translocation, demonstrating that
AIF release was indeed PARylation dependent (Figure S2D). By
limiting the cellular PARylation capacity, TRIP12 thus affects mul-
tiple outcomes of PAR formation in response to genotoxic stress.
Cooperation betweenaPAR-BindingWWEDomain anda
HECT-Type Ubiquitin Ligase Domain Enables PAR-
Targeted Ubiquitylation
Next, we aimed to elucidate themechanism of PARP1 regulation
by TRIP12. We found ectopically expressed TRIP12 to interact
(E) Naive U-2OS cells (first lane) and U-2OS PARP1 knockout (KO) cells transfected withMyc-PARP1 and increasing amounts of GFP-TRIP12 (0, 1, 2, and 4 mg of
plasmid, respectively) were analyzed for PARP1 levels by western blot.
(F) U-2 OS transfected with GFP-TRIP12 were analyzed by high-content microscopy for GFP-TRIP12 and endogenous PARP1 levels. Nuclear GFP-TRIP12 and
PARP1 intensities per cell are plotted, color-coded by GFP-TRIP12 expression. Representative single cell images are shown to the right. Scale bar, 10 mm.
See also Figure S1.




Figure 2. TRIP12 Limits PARylation and Affects Outcomes of PAR Signaling
(A) U-2 OS cells were transfected with the indicated siRNAs and localized DNA damage was induced by laser micro-irradiation. Cells were allowed to recover for
the indicated time periods and stained for gH2AX as DNA damage marker and PARP1. Representative single cell images are shown and quantification of PARP1
recruitment to sites of DNA damage is depicted below as mean ± SD. ***, p < 0.001; **, p < 0.01.
(B) U-2OS cells were treated as in (A) and stained for gH2AX and PAR. Representative single cell images are shown and quantification of PAR formation at sites of
DNA damage is depicted below as mean ± SD. ***, p < 0.001; **, p < 0.01.
(C) U-2OS cells were treated as in (A) and stained for gH2AX and XRCC1. Representative single cell images are shown and quantification of XRCC1 recruitment to
sites of DNA damage is depicted below as mean ± SD. **, p < 0.01.
(D) U-2 OS cells were treated as in (A) and stained for gH2AX andMDC1. Representative single cell images are shown and quantification of MDC1 recruitment to
sites of DNA damage is depicted below as mean ± SD.
See also Figure S2.




with PARP1, and this interaction was impaired by PARPi (Fig-
ure 3A). We also observed an interaction between endogenous
TRIP12 and PARP1, although only upon treatment with PARGi
to stabilize PARP1 auto-PARylation under otherwise unchal-
lenged conditions (Figure S3A). Applying PARPi in conjunction
with PARGi greatly reduced this interaction (Figure S3B). Consis-
tently, a PARylation-defective mutant (PARP1 E988K) showed
reduced binding to TRIP12 compared to wild-type PARP1 (Fig-
ure S3C). As TRIP12 contains a putative PAR-binding WWE
domain, we expressed and purified the TRIP12 WWE domain
(amino acids 797–911) as a GST-fusion protein and tested
whether it would directly interact with auto-PARylated PARP1.
Figure 3. TRIP12 Interacts with and Poly-
Ubiquitylates PARP1 in a PAR- and WWE-
Dependent Manner
(A) HEK293T cells were transfected with the indi-
cated plasmids for co-immunoprecipitation (coIP)
experiments, with or without prior PARPi treat-
ment (olaparib: 10 mM, 1 h). FLAG-PARP1 was
immunoprecipitated and the interaction with GFP-
PARP1 was analyzed by western blot. IP samples
were adjusted based on input levels of PARP1 to
correct for the effect of TRIP12 on PARP1 abun-
dance.
(B) In vitro interaction assay of purified GST, GST-
TRIP12-WWE wild type (WT), and GST-TRIP12-
WWE R869A mutant with PARP1 and auto-
PARylated PARP1. Recombinant purified PARP1
was incubated or not with a low (20 mM, +) or high
(200 mM, ++) concentration of NAD+ for 15 min at
30C to induce PARP1 auto-PARylation prior to
the GST interaction assay. PARP1 and PAR
binding to the purified GST-fusion proteins was
assessed by western blot.
(C) Ex vivo interaction assay of purified GST, GST-
TRIP12-WWEWT, and GST-TRIP12-WWE R869A
mutant with whole cell lysates from HeLa cells,
which were exposed to 1-mM H2O2 for 15 min
prior to cell lysis to induce PAR formation. PARG
was depleted from these cells by siRNA to avoid
the PARG-mediated rapid degradation of PAR.
PARP1 and PAR binding to the purified GST-
fusion proteins was assessed by western blot.
(D) In vitro ubiquitylation assay with purified E1
(UBE1), E2 (UBE2L3), E3 (FLAG-TRIP12WT,WWE
mutant (R869A), or HECT mutant (C2034A) puri-
fied from HEK293T cells and ubiquitin, using auto-
PARylated PARP1 as a target protein. PARP1
ubiquitylation was assessed by western blot with
anti-ubiquitin antibody. TRIP12 levels were as-
sessed by running the supernatant from the in vitro
reaction via western blot.
(E) In vivo ubiquitylation assay in HEK293T cells
expressing FLAG-PARP1 and GFP-TRIP12 WT,
WWE mutant (R869A), or HECT mutant (C2034A)
together with HA-ubiquitin. FLAG-PARP1 was
immunoprecipitated and PARP1 ubiquitylation
was assessed by western blot. IP samples were
adjusted based on input levels of PARP1 to correct
for the effect of TRIP12 on PARP1 abundance.
(F) In vitro ubiquitylation assay to monitor TRIP12
activity in absence or presence of purified PAR
chains. FLAG-TRIP12 WT or the PAR-binding-
deficient WWE mutant (R869A) were purified from
HEK293T cells and incubated with E1 (UBE1), E2
(UBE2L3), and ubiquitin with or without different
amounts of purified PAR chains as indicated.
Auto-ubiquitylation of TRIP12 was assessed by
western blot.
See also Figure S3.




As an additional specificity control, we generated a mutant
version containing a single amino acid exchange (TRIP12
WWE R869A), which, based on sequence alignment with other
WWE domains (Wang et al., 2012; see also Figure 1B), would
be predicted to abolish PAR binding. These in vitro interaction
experiments revealed that the TRIP12 WWE domain indeed
bound PARP1, and that the interaction was strongly dependent
on PARP1 auto-PARylation (Figure 3B). Consistently, the purified
wild-type WWE domain of TRIP12, but not the R869A mutant,
precipitated PARylated proteins, including PARP1, from H2O2-
treated cell extracts (Figure 3C). Moreover, in co-immunoprecip-
itation experiments, the interaction between TRIP12 and PARP1
was reduced for the TRIP12 WWE domain mutant R869A
(Figure S3D).
To directly test whether TRIP12 functions as PAR-targeted
ubiquitin ligase (PTUbL; Pellegrino and Altmeyer, 2016) for
PARP1, we reconstituted the ubiquitylation reaction in vitro using
purified E1 and E2 enzymes, auto-PARylated PARP1, and im-
muno-purified full-length TRIP12. Although wild-type TRIP12
was indeed able to ubiquitylate PARP1, neither the TRIP12
WWE mutant (R869A), nor a catalytically inactive mutant con-
taining a single amino acid exchange in the HECT ubiquitin ligase
domain (C2034A), was able to modify PARP1 (Figure 3D). Impor-
tantly, also when expressed in cells, TRIP12 wild type, but not
the WWE (R869A) and HECT domain (C2034A) mutants, trig-
gered PARP1 ubiquitylation (Figure 3E). Thus, TRIP12 catalyzes
PARP1 ubiquitylation in a PAR-dependent manner.
For the RING-type ubiquitin ligase RNF146/Iduna, an allosteric
mechanism of PAR-dependent activation was described (DaR-
osa et al., 2015); we therefore reasoned that a similar mechanism
might be at work for the HECT-type ubiquitin ligase TRIP12.
Indeed, addition of purified PAR chains greatly stimulated the
enzymatic activity of TRIP12, and this effect was abolished
when the PAR-binding-deficient WWE mutant (R869A) was
used (Figure 3F). Taken together, our in vitro and in vivo results
thus provide biochemical support for an allosteric mechanism
to activate TRIP12 in a PAR-binding- and WWE-domain-depen-
dent manner. With analogous mechanisms being employed by
both RING-type (RNF146/Iduna) and HECT-type (TRIP12) ubiq-
uitin E3 ligases, PAR-binding-mediated allosteric activation
seems to be a general mechanism for activation of and target
protein recognition by WWE-containing ubiquitin E3 ligases.
In line with the ubiquitylation data, overexpression of wild-type
TRIP12 reduced PARP1 levels, while overexpression of the
WWE (R869A) and HECT domain (C2034A) mutants had no ef-
fect (Figure 4A). Conversely, depletion of TRIP12 resulted in
reduced ubiquitylation of PARP1 in cells (Figure 4B). TRIP12
depletion also stabilized PARP1 in cycloheximide (CHX) experi-
ments, an effect that was partially masked by reduced TRIP12
expression after prolonged CHX exposure (Figure 4C). Similarly,
inhibition of PAR formation by the PARPi PJ-34 stabilized PARP1
levels, and additional depletion of TRIP12 did not result in a
further increase in PARP1, consistent with PAR-dependent turn-
over of PARP1 by TRIP12 (Figures 4D and S4A). Reassuringly,
the elevated PARP1 abundance upon TRIP12 depletion was
rescued by siRNA-resistant wild-type TRIP12, but not by the
catalytically inactive C2034A mutant or by the PAR binding-defi-
cient R869A mutant (Figure 4E), despite all TRIP12 versions be-
ing expressed at similar levels (Figure S4B). Moreover, short-
term inhibition of the proteasome stabilized PARP1 upon
TRIP12 overexpression (Figure 4F), in agreement with PAR-
dependent, proteasome-mediated degradation of PARP1.
Finally, we also found TRIP12 to be recruited to sites of DNA
damage in a PAR-, PARP1-, and WWE-domain-dependent
manner (Figures S4C and S4D), indicating that TRIP12 not only
controls basal PARP1 levels but also participates in PAR-trig-
gered protein ubiquitylation in response to genotoxic stress.
Taken together, our in vitro and in vivo data reveal that through
its PAR-binding WWE domain and the carboxy-terminal HECT
domain TRIP12 functions as PTUbL, which controls PARP1
abundance and activity.
TRIP12 Constrains PARP1 Trapping and Extenuates
PARPi-Induced Genotoxicity
As PARP1 is the major target of PARPi, and given that PARPi-
induced cancer cell death has been associated with cytotoxic
PARP1 trapping, entailing replication problems during S-phase
progression and DNA damage (Michelena et al., 2018; Murai
et al., 2012; Muvarak et al., 2016; Zimmermann et al., 2018), we
wondered whether TRIP12might impact this aspect of PARPi ac-
tion. Loss of TRIP12 indeed resulted in enhanced chromatin asso-
ciation of PARP1 (in unchallenged conditions and more pro-
nounced upon PARPi and when PARPi was combined with
alkylation damage by methyl methanesulfonate [MMS]), both
when quantifying the detergent-resistant pool of PARP1 in hun-
dreds of individual cells by high-content microscopy and also in
biochemical fractionation assays (Figures 5A, 5B, S5A, and
S5B). Consistent with elevated PARP1 trapping upon impaired
TRIP12 function, we observed an increase in DNA damage
signaling marked by gH2AX, primarily in the S- and G2-phase of
the cell cycle (Figures 5C and S5C). DNA damage signaling
upon PARPi is associated with impaired S-phase progression
and G2/M arrest (Michelena et al., 2018), and we observed a
more pronounced PARPi-evoked accumulation of cells in G2/M
upon TRIP12 depletion, compared to control cells (Figure 5D).
Importantly, both the increased DNA damage signaling measured
by gH2AX formation aswell as themore pronounced cell cycle ar-
rest were rescued by PARP1 co-depletion (Figures S5D and S5E),
indicating that these signs of genotoxic stress were caused by
catalytically inactivated PARP1. Also, additional markers of
PARPi-induced genotoxic stress, such as replication-associated
formation of 53BP1, RAD51 and RPA foci, were elevated in
TRIP12-depleted cells, and PARP1 co-depletion alleviated these
effects (Figures 5E–5G). Collectively, these results provide evi-
dence that TRIP12, by limiting PARP1 abundance and PARP trap-
ping, extenuates PARPi-induced DNA damage.
Downregulation of TRIP12 Sensitizes Cancer Cells to
PARPi and Is Associated with Elevated PARP1
Abundance in Cancer Patients
Finally, to directly test whether TRIP12 status determines cancer
cell survival upon PARPi exposure, we performed colony forma-
tion assays in multiple cell lines. Remarkably, TRIP12 downregu-
lation greatly sensitized BRCA-proficient cancer cells to the
PARPi olaparib, and the hyper-sensitization was strictly depen-
dent on the presence of PARP1, as PARP1 co-depletion rescued




clonogenic survival in all cases (Figures 6A–6D). Similar results
were obtained with a second and third siRNA against TRIP12
(Figures S6A and S6B) and with two different clinically approved
PARPi, rucaparib and talazoparib (Figures S6C and S6D).
Consistent with the hyper-sensitization to PARPi originating
from supra-physiological PARP1 accumulation, TRIP12 deple-
tion had no effect on the survival of PARP1 KO cells (Figure S6E).
These results are consistent with the notion that PARP1, locked
in a catalytically nonproductive state, is an important contributor
to PARPi-induced cell death in BRCA-proficient cells, and sug-
gest that variations in PARP1 protein levels impact PARPi sensi-
tivity. In line with this, controlled overexpression of PARP1 in a
stable doxycycline-inducible cell line resulted in reduced survival
upon PARPi (Figure S6F).
As our findings suggested that TRIP12 expression might serve
as an indicator of PARP1 stability (and thus PARP1 abundance
Figure 4. TRIP12 Controls PARP1 Stability and Proteasomal Degradation in a PAR-Dependent Manner
(A) U-2 OS PARP1 KO cells were transfected with the indicated plasmids and the effect of GFP-TRIP12 WT or mutant expression on Myc-PARP1 levels was
assessed by western blot.
(B) U-2 OS cell were transfected with control siRNA or siRNA against TRIP12 for 48 h, followed by the indicated plasmid transfections for 24 h. Myc-PARP1 was
immunoprecipitated and its ubiquitylation was assessed by western blot with an anti-HA antibody. Immunoprecipitation with a FLAG antibody was performed to
detect unspecific binding. IP samples were adjusted based on input levels of PARP1 to correct for the effect of TRIP12 on PARP1 abundance.
(C) U-2 OS were transfected with control siRNA or siRNA against TRIP12 and exposed to cycloheximide (CHX, 50 mM) for the indicated time periods. TRIP12 and
PARP1 levels were assessed by western blot. PARP1 band intensities were quantified in Fiji and the fold changes are indicated below.
(D) U-2OSwere transfectedwith control siRNA or siRNA against TRIP12 and exposed to a PARPi with low PARP1 trapping activity (PJ-34, 10 mM) as indicated for
16 h to block PARylation with minimal cytotoxicity. TRIP12 and PARP1 levels were assessed by western blot.
(E) U-2 OS cells were transfected with control siRNA or siRNA against TRIP12 for 48 h, followed by the indicated plasmid transfections for 24 h. All TRIP12
plasmids were rendered siRNA-resistant by introducing multiple silent mutations. High-content imaging-derived violin plot show nuclear PARP1 intensities.
Median (solid lines) and quartiles (dashed lines) are indicated.
(F) U-2 OS PARP1 KO cells were transfected with plasmids forMyc-PARP1 andGFP-TRIP12 expression and exposed to the proteasome inhibitor MG132 (10 mM)
as indicated. PARP1 levels were assessed by western blot.
See also Figure S4.
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and consequently PARPi sensitivity), we explored the NCI/NIH
CPTAC Data Portal (Edwards et al., 2015; Ellis et al., 2013) for
studies providing matched genotyping, gene expression, and
protein abundance data.We identified suchmatchedmultiomics
data for cohorts of 102 breast cancer patients and 145 ovarian
cancer patients. In both cohorts, TRIP12 expression showed a
negative correlation with PARP1 protein abundance (Figures
6E, 6F, S7A, and S7B), consistent with ourmechanistic and func-
tional data. BRCA status did not provide information about
PARP1 abundance in these patient cohorts (Figures 6E, 6F,
S7C, and S7D), suggesting that the negative correlation between
TRIP12 expression and PARP1 abundance is unrelated to BRCA
function. In summary, our findings establish TRIP12 as a PTUbL,
which constrains PARP1 abundance and PARPi efficiency, and
suggest that TRIP12 measurements might be useful to evaluate
PARPi sensitivity beyond BRCA mutations (Figures 7A and 7B).
DISCUSSION
BRCA deficiency has emerged as paradigm for PARPi sensitivity,
with impaired BRCA function leading to synthetic lethality in
PARPi-exposed cancer cells. Here, we reveal a mechanistically
distinct synthetic lethal/sick relationship between PARPi and
impaired TRIP12 function. While BRCA defects entail HDR defi-
ciency with a compromised capacity to protect stalled replication
forks and deal with DNA double-stand breaks, TRIP12 dysfunc-
tion leads to supra-physiological PARP1 levels and causes hy-
per-sensitization to PARPi by elevated PARP1 trapping. Hence,
concomitant loss of PARP1 reverses PARPi sensitivity under con-
ditions of impaired TRIP12 function, in contrast to the synthetic
lethality caused by BRCA deficiency. It was recently demon-
strated that mutations in PARP1 that disrupt its interaction with
DNA and alleviate PARP1 trapping provide protection fromPARPi
cytotoxicity and may underlie clinical cases of PARPi resistance
(Pettitt et al., 2018). It will thus be important to evaluate whether
additional cases of PARP1 mutations associated with PARPi
resistance may emerge from currently ongoing PARPi trials, and
whether upregulation of TRIP12may provide an alternativemeans
for cancer cells to escape PARPi therapy.
PARPi monotherapy has demonstrated promising results in
specific patient cohorts, in particular in germline BRCAmutation-
associated breast and ovarian cancer. Olaparib showed a
response rate of 41% in germline BRCA mutated carriers with
recurrent, advancedbreast cancer (Tutt et al., 2010), and response
rates of 31%–40% were reported in germline mutated BRCA
ovarian cancer patients with recurrent disease (Fong et al.,
2010). Recently, data presented from a randomized phase III trial,
which compared single-agent olaparib with chemotherapy treat-
ment of physician’s choice (TPC) in germline BRCAmutated plat-
inum-sensitive relapsed ovarian cancer, showed favorable out-
comes of olaparib over TPC with objective response rate of 72%
versus 51% (Penson et al., 2020). However, predicting PARPi
sensitivity has remained challenging due to the lack of good bio-
markers, in particular beyond BRCA- and HDR-deficiencies.
PARP1 and PARP activity measurements have been proposed
as predictive tools (Coskun et al., 2019; Makvandi et al., 2016;
Makvandi et al., 2018; Oplustilova et al., 2013; Thomas et al.,
2018), but PARP1 gene expression does not necessarily reflect
PARP1 protein abundance, and PARP activity measurements
may not necessarily predict PARP1 trapping. Moreover, anti-
body-based detection of PAR and PARP1 has limitations in terms
of sensitivity and specificity. Therefore, additional markers for
PARPi efficiency are needed. Based on themolecular mechanism
of TRIP12-mediated PARP1 turnover described here and the in-
verse correlation between TRIP12 expression and PARP1 abun-
dance in cohorts of breast and ovarian cancer patients, we pro-
pose that evaluation of TRIP12 status could provide such an
additional stratification marker for PARP1 abundance and PARPi
sensitivity, and for PARPi single agent and combination therapies.
Validation of TRIP12-mediated PARP1 turnover and its effect on
PARPi efficiency in suitable animal models would help address
this point further. Additionally, once data become available from
cancer patients treated with PARPi that allow for comparison of
TRIP12 status, PARP1 protein abundance, and PARPi response,
a clinical evaluation of the relationship between TRIP12 status
and PARPi response will be possible.
WWE-dependent PAR binding and PAR-targeted ubiquitylation
has been primarily characterized for the RING domain ubiquitin
ligase RNF146/Iduna (DaRosa et al., 2015; Wang et al., 2012;
Zhang et al., 2011). A crystal structure of the RNF146/Iduna
RING-WWE domains together with iso-ADPr revealed a mecha-
nism of RING-type ubiquitin E3 ligase activation by PAR
Figure 5. TRIP12 Constrains PARP1 Trapping and Extenuates PARPi-Induced DNA Damage
(A) U-2OS cells transfected with control siRNA or siRNA against TRIP12 and exposed toMMS (0.01%) and PARPi (olaparib, 10 mM) for 1 h as indicated. Cells were
pre-extracted and chromatin-bound PARP1 was analyzed by high-content microscopy. Violin plots with median (solid lines) and quartiles (dashed lines) are
shown; unpaired t test was used for statistical analysis. Representative single cell images of endogenous chromatin-bound PARP1 are shown below. Scale bar,
10 mm. ****, p < 0.0001.
(B) U-2 OS cells transfected with control siRNA or siRNA against TRIP12 were treated with MMS (0.01%) and PARPi (olaparib, 10 mM) for 2 h as indicated. Cells
were then subjected to chromatin fractionation to separate the soluble from the chromatin-bound fraction. Chromatin-bound PARP1 was analyzed by western
blot. PARP1 band intensities were quantified in Fiji and the fold changes are indicated below.
(C) HeLa Kyoto PARP1-LAP cells were transfected with control siRNA or siRNA against TRIP12 and exposed to PARPi (olaparib, 10 mM) for 16 h. QIBC-derived
cell cycle resolved gH2AX profiles are shown. Representative single-cell images of gH2AX staining are shown below. Scale bar, 10 mm.
(D) QIBC-derived EdU profiles are shown and percentages of cells in G1, S, and G2 are provided for the same cells analyzed in (C).
(E) U-2 OS cells were transfected with siRNAs and exposed to PARPi (olaparib, 10 mM) as indicated. QIBC-derived cell cycle resolved profiles of nuclear 53BP1
foci are shown. Representative single-cell images of 53BP1 foci are shown to the right. Scale bar, 10 mm.
(F) U-2 OS cells were treated as in (E) and QIBC-derived cell-cycle resolved profiles of nuclear RAD51 foci are shown. Representative single cell images of RAD51
foci are shown to the right. Scale bar, 10 mm.
(G) U-2 OS cells were treated as in (E) and QIBC-derived cell-cycle resolved profiles of nuclear RPA foci are shown. Representative images of RPA foci are shown
to the right. Scale bar, 10 mm.
See also Figure S5.




binding-induced allosteric conformational changes leading to a
functional RING structure (DaRosa et al., 2015). Although struc-
tural information on the precise interplay between the WWE and
HECT domains of TRIP12 is currently not available, our biochem-
ical and functional data suggest that a similar allosteric mecha-
nism, triggered by non-covalent PAR binding, might stimulate
the catalytic activity of the HECT-type ubiquitin E3 ligase
TRIP12. Further studies and dedicated protein structure illumina-
tion will be needed to elucidate the conformational changes un-
derlying PAR-triggered activation of the two families of ubiquitin
ligases, the RING domain, and the HECT domain ligases, and
how they affect their respective reaction mechanism (direct ubiq-
uitin transfer from E2 to the substrate by RING domain enzyme
versus ubiquitin conjugation to an active-site cysteine by HECT
domain enzymes). Of note, RNF146/Iduna was previously shown
to bind and ubiquitylate PARylated PARP1 among other
Figure 6. Downregulation of TRIP12 Sensitizes Cancer Cells to PARPi and Is Associatedwith Elevated PARP1 Abundance in Cancer Patients
(A) U-2 OS cells were transfected with siRNAs and exposed to PARPi olaparib as indicated for clonogenic survival assays. Relative clonogenic survival in
response to increasing doses of PARPi olaparib is shown. Means ± SD are depicted.
(B) HeLa Kyoto PARP1-LAP cells were treated as in (A) and relative clonogenic survival in response to increasing doses of PARPi olaparib is shown. Means ± SD
are depicted.
(C) HCC1143 cells were treated as in (A) and relative clonogenic survival in response to increasing doses of PARPi olaparib is shown. Means ± SD are depicted.
(D) MCF-7 cells were treated as in (A) and relative clonogenic survival in response to increasing doses of PARPi olaparib is shown. Means ± SD are depicted.
(E) Scatterplot of adjusted PARP1 protein levels against the relative TRIP12 RNA expression in breast cancer, with BRCA mutant samples highlighted in red.
Upper right shows p values and r in Pearson’s product-moment correlation tests.
(F) As in (E) for the ovarian cancer samples. Upper right shows p values and r in Pearson’s product-moment correlation tests.
See also Figure S6.




PARylated proteins (Kang et al., 2011), and the mitotic checkpoint
factor and RING-type ubiquitin ligase CHFR targets PARP1 for
degradation upon mitotic stress and DNA damage (Kashima
et al., 2012; Liu et al., 2013). Also, RNF168 acts on PARP1 and
regulates PARP1-dependent repair functions (Kim et al., 2018).
It will thus be interesting to investigate how RING- and HECT-
type ubiquitin ligases functionally cooperate to regulate PARP1
degradation, and how this in turn affects PARPi-induced PARP1
trapping in different cell cycle phases and at different types of
DNA lesions. Our results show that TRIP12 regulates PARP1
steady-state levels in unchallenged conditions, indicating that
basal PARP1 activity (which is hardly detectable by PAR anti-
bodies), likely triggered by endogenous DNA lesions, is sufficient
for TRIP12 to bind PARP1 and regulate its turnover. However, we
also found TRIP12 to be recruited to sites of DNA damage in a
PARP1- and PAR-dependent manner, suggesting that TRIP12,
as PAR-targeted ubiquitin ligase (PTUbL), additionally controls
the strength and duration of PAR signaling upon genotoxic insults.
A limited number of TRIP12 targets had been identified by pre-
vious studies; however, whether their ubiquitylation is stimulated
by prior PARylation is currently not known. For instance, TRIP12
catalyzes amino-terminal ubiquitylation of several substrates of
the ubiquitin fusion degradation (UFD) pathway (Park et al.,
2009), and also controls the half-life and abundance of the tumor
suppressor and p53 activator p14/ARF in non-cancer cells (Chen
et al., 2010). Moreover, TRIP12 was previously identified as a
negative regulator of the DNA damage response protein
RNF168, which promotes regulatory chromatin-associated ubiq-
uitylation events and coordinates the recruitment of downstream
genome caretakers in response to DNA replication stress and
chromosome breakage (Gudjonsson et al., 2012). Based on the
emerging paradigm of PAR-dependent ubiquitylation, future
studies may discern PAR-dependent and -independent functions
of TRIP12 and aim for comprehensive identification of TRIP12 tar-
gets in different cells lines, to elucidate their roles for genome sta-
bility and chemotherapy sensitivity and resistance.Moreover, with
the intensified development of ubiquitin E3 ligase inhibitors, small
molecules targeting TRIP12 may soon become available to test
combined inhibition of PARPs and TRIP12 in order to maximize
PARPi-induced PARP trapping and PARPi efficiency.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
H2AX Phospho S139 primary antibody
(mouse)
Biolegend Cat# 613401; RRID:AB_315794
H2AX Phospho S139 primary antibody
(rabbit)
Cell Signaling Cat# 2344; RRID:AB_2118009
TRIP12 primary antibody (rabbit) Bethyl Cat# A301-814A; RRID:AB_1264344
PARP1 primary antibody (rabbit) Abcam Cat# ab227244; RRID:N/A
PARP1 (H-250) primary antibody (mouse) Santa-Cruz Cat# sc-7150; RRID:AB_2160738
c-Myc primary antibody (mouse) Santa-Cruz Cat# sc-40; RRID:AB_627268
Poly(ADP-ribose) primary antibody (rabbit) Enzo Life Sciences Cat# ALX-210-890-R100;
RRID:AB_2052276
RPA70 primary antibody (rabbit) Abcam Cat# ab79398; RRID:AB_1603759
53BP1 primary antibody (rabbit) Santa-Cruz Cat# sc-22760; RRID:AB_2256326
53BP1 primary antibody (mouse) Millipore Cat# MAB3802; RRID:AB_2206767
AIF primary antibody (rabbit) Santa-Cruz Cat# sc-5586; RRID:AB_2224668
FLAG primary antibody (mouse) Sigma-Aldrich Cat# F3165; RRID:AB_259529
Ubiquitin (P4D1) primary antibody (mouse) Santa-Cruz Cat# sc-8017; RRID:AB_628423
HA.11 primary antibody (mouse) BioLegend Cat# 901513; RRID:AB_2565335
RAD51 primary antibody (rabbit) BioAcademia Cat# 70-002
XRCC1 primary antibody (mouse) Novus Biologicals Cat# H00007515-B01P; RRID:AB_1522704
MDC1 primary antibody (rabbit) Abcam Cat# ab11171; RRID:AB_297810
RNF168 primary antibody (rabbit) Stewart et al., 2009 N/A
Tubulin primary antibody (mouse) Sigma-Aldrich Cat# T6199; RRID:AB_477583
Histone H3 primary antibody (rabbit) Abcam Cat# ab1791; RRID:AB_302613
PARP2 primary antibody (rabbit) Active Motif Cat# 39743; RRID:AB_2793328
GFP primary antibody (rabbit) Torrey Pines Biolabs Cat# TP401 071519; RRID:AB_10013661
Alexa Fluor 488 goat-anti-Mouse ThermoFisher Cat# A-11029; RRID:AB_2534088
Alexa Fluor 488 goat-anti-Rabbit ThermoFisher Cat# A-11034; RRID:AB_2576217
Alexa Fluor 568 goat-anti-Mouse ThermoFisher Cat# A-11031; RRID:AB_144696
Alexa Fluor 568 goat-anti-Rabbit ThermoFisher Cat# A-11036; RRID:AB_10563566
Alexa Fluor 647 goat-anti-Mouse ThermoFisher Cat# A-21235; RRID:AB_2535804
Alexa Fluor 647 goat-anti-Rabbit ThermoFisher Cat# A-21244; RRID:AB_2535812
Anti-Mouse IgG (H+L), Peroxidase AdipoGen Life Science Cat# VC-PI-2000-M001
Anti-Rabbit IgG (H+L), Peroxidase AdipoGen Life Science Cat# VC-PI-1000-M001
Bacterial and Virus Strains
Library Efficiency DH5a Competent Cells ThermoFisher Cat# 18263012
BL21 (DE3) competent cells ThermoFisher Cat# EC0114
Chemicals, Peptides, and Recombinant Proteins
Q5 High-Fidelity DNA polymerase New England Biolabs Cat# M0491S
T5 Exonuclease New England Biolabs Cat# M0363S
Taq DNA ligase New England Biolabs Cat# M0208S
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dATP Sigma-Aldrich Cat# D4788
dCTP Sigma-Aldrich Cat# D4913
dGTP Sigma-Aldrich Cat# D5038
dTTP Sigma-Aldrich Cat# 11969048001
Dulbecco’s modified Eagle’s medium
(DMEM)
ThermoFisher Cat# 61965-026
RPMI-1640 medium ThermoFisher Cat# A1049101
Ham’s F12 medium ThermoFisher Cat# 11765054
OptiMEM ThermoFisher Cat# 31985070
Tet system approved fetal bovine serum Clontech Cat# 631107
Bovine Serum Albumin Sigma-Aldrich Cat# A9418
Penicillin-streptomycin ThermoFisher Cat# 15140-122
Hygromycin B ThermoFisher Cat# 10687010
Geneticin (G418 sulfate) ThermoFisher Cat# 10131027
5-bromo-2-deoxyuridine (BrdU) Sigma-Aldrich Cat# B5002
PJ-34 Enzo Life Sciences Cat# ALX-270-289-M001
Rucaparib Selleckchem Cat# S1098
Talazoparib Selleckchem Cat# S1288
Hydrogen peroxide Sigma-Aldrich Cat# H3410
Olaparib Selleckchem Cat# S1060
Methylmethanesulfunate Sigma-Aldrich Cat# 129925
PARG inhibitor Tocris Cat# 5952
FK866 Sigma-Aldrich Cat# F8557
MG132 Sigma-Aldrich Cat# M7449
Doxycycline Sigma-Aldrich Cat# D9891
Cycloheximide Sigma-Aldrich Cat# C7698
TRIzol reagent ThermoFisher Cat# 15596026
Random hexamers Roche Cat# 11034731001
Protease inhibitor cocktail cOmplete Roche Cat# 11873580001
PhosSTOP Roche Cat# 4906837001
S7 Nuclease Sigma-Aldrich Cat# 10107921001
Benzonase Merck Cat# 71206-3
3x FLAG peptide Sigma-Aldrich Cat# F4799
Glycine Sigma-Aldrich Cat# G8898
UBE1 Boston Biochem Cat# E-305
UBE2L3 Boston Biochem Cat# E2-640
Ubiquitin Boston Biochem Cat# U-100H
hPARP1 Michael Hottiger N/A
hPARG Michael Hottiger N/A
PAR polymer Trevigen Cat# 4336-100-01
TRIP12 WWE domain WT This paper N/A
TRIP12 WWE domain R869A This paper N/A
Protein G Sepharose 4 Fast Flow GE Healthcare Cat# 17-0618-01
ProBond Nickel resin ThermoFisher Cat# R80101
DAPI ThermoFisher Cat# D1306
Mowiol 4.88 Calbiochem Cat# 475904
(Continued on next page)
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Critical Commercial Assays
Rapid Ligation kit Roche Cat# 11635379001




Lipofectamine 3000 ThermoFisher Cat# L3000008
MultiScribe Reverse Transcriptase ThermoFisher Cat# 4311235
KAPA Biosystems Sybr Fast qPCR Kit Roche Cat# KK4600
Lipofectamine RNAiMAX ThermoFisher Cat# 13778-150
QIAGEN MinElute PCR Purification Kit QIAGEN Cat# 28004
Energy regeneration System Boston Biochem Cat# B-10
Experimental Models: Cell Lines
U-2 OS (female origin, STR authenticated) ATCC Cat# HTB-96; RRID:CVCL_0042
hTERT-RPE1 (female origin) ATCC Cat# CRL-4000; RRID:CVCL_4388
HEK293T (female origin) ATCC N/A
MCF-7 (female origin) Ross Chapman N/A
U-2 OS PARP1 KO (female origin) Keith Caldecott N/A
HeLa (female origin) Raffaella Santoro N/A
HeLa Kyoto PARP1-LAP cells (female
origin)
Stoyno S. Stoynov N/A
HCC1143 (female origin) Mohamed Bentires-Alj N/A
U-2 OS Tet-ON (female origin) Ana Zubiaga N/A
U-2 OS Tet-ON HA-empty vector control
cells
This paper N/A
U-2 OS Tet-ON HA-PARP1 cells This paper N/A
Oligonucleotides
See Table S1 N/A
Recombinant DNA
pcDNA-Myc-PARP1 WT Laboratory of Michael Hottiger N/A
pcDNA-Myc-PARP1 E988K Laboratory of Michael Hottiger N/A
pCMV-FLAG-PARP1 Laboratory of Michael Hottiger N/A
pcDNA-HA-Ubiquitin Laboratory of Lorenza Penengo N/A
pAc-GFP-C1 TRIP12 WT This paper N/A
pAc-GFP-C1 TRIP12 C2034A This paper N/A
pAc-GFP-C1 TRIP12 R869A This paper N/A
pAc-GFP-C1 TRIP12 WT siRNA resistant This paper N/A
pAc-GFP-C1 TRIP12 C2034A siRNA
resistant
This paper N/A
pAc-GFP-C1 TRIP12 R869A siRNA
resistant
This paper N/A
pcDNA 3.1 FLAG TRIP12 WT This paper N/A
pcDNA 3.1 FLAG TRIP12 C2034A This paper N/A
pcDNA 3.1 FLAG TRIP12 R869A This paper N/A
pGEX 6P-1 TRIP12 WWE WT This paper N/A
pGEX 6P-1 TRIP12 WWE R869A This paper N/A
pTRE2Hyg2-HA-PARP1 WT This paper N/A
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Matthias
Altmeyer (matthias.altmeyer@uzh.ch).
Materials Availability
Materials generated in this study will be made available upon reasonable request to the Lead Contact.
Data and Code Availability
This study did not generate or analyze code or datasets (such as microarray, genomics, transcriptomics, protein structure data).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and culture conditions
Human U-2 OS cells (ATCC), RPE-1 (ATCC), HEK293T (ATCC), HeLa (kindly provided by Raffaella Santoro), MCF-7 (kindly provided
by Ross Chapman), U-2 OS PARP1 KO cells (kindly provided by Keith Caldecott), HeLa Kyoto PARP1-LAP cells stably expressing
EGFP-tagged PARP1 from its natural promoter (kindly provided by Stoyno S. Stoynov), and TetOn HA-PARP1 U-2 OS cells were
grown under standard sterile cell culture conditions (37C, humidified atmosphere, 5%CO2) in Dulbecco’s modified Eagle’s medium
(DMEM, Thermo Fisher Scientific) containing 10% fetal bovine serum (GIBCO) and 1% of penicillin-streptomycin antibiotics.
HCC1143 cells (kindly provided by Mohamed Bentires-Alj) were grown in RPMI-1640 medium (Thermo Fisher Scientific) containing
10% fetal bovine serum (GIBCO) and 1% penicillin-streptomycin antibiotics. All cultured cells were routinely tested for mycoplasma
contamination and scored negative. In addition, cells were regularly assessed by quantitative image-based cytometry (QIBC) for
proper proliferation and absence of abnormal stress signals.
Bacterial strains
Cloning was done using chemically competent bacteria generated in-house, derived from Library Efficiency DH5a Competent Cells
(ThermoFisher), and recombinant protein expression from BL21 (DE3) competent cells.
METHOD DETAILS
Generation of doxycycline-inducible HA-PARP1 cell line
pTREHyg2-HA was linearized with Phusion High-Fidelity polymerase using primers pTRE2Hyg2_lin_frw and pTRE2Hyg2_lin_rev.
PARP1 was amplified with Phusion polymerase using primers PARP1 GA_to_pTRE_fwr and PARP1 GA_to_pTRE_rev. The amplified
products were DpnI digested and purified by gel extraction followed by isothermal Gibson assembly. U-2 OS TetOn cells (kindly pro-
vided by Ana Zubiaga) stably expressing PARP1were generated by transfection of pTRE2Hyg2-HA containing the PARP1 sequence.
Induction of PARP1 expression was achieved by Doxycycline treatment (1000ng/ml).
Drug treatment
The following compounds were used at the indicated final concentrations: PJ-34 (10 mM, ALX-270-289-M001, Enzo Life Science),
Olaparib (1-10 mM, AZD-2281, Selleckchem), Rucaparib (1-8 mM, AG-014699, Selleckchem), Talazoparib (6.25-50 nM, BMN673,
Selleckchem), b-Nicotinamide adenine dinucleotide hydrate (20-200 mM, N7004, Sigma-Aldrich), hydrogen peroxide (0.02-
0.5 mM, H3420, Sigma-Aldrich), Methyl methanesulfunate, MMS (0.01%, 129925, Sigma-Aldrich), PARG inhibitor (10 mM,
PDD00017273, Tocris), FK866 (1 mM, F8557, Sigma-Aldrich), MG132 (10 mM, M7449, Sigma-Aldrich), cycloheximide (50 mM,
C7698, Sigma-Aldrich).
Continued
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Software and Algorithms
GraphPad Prism 8.0 GraphPad Software https://www.graphpad.com/




TIBCO Spotfire 7.0.1 TIBCO Software https://spotfire.tibco.com/
Fiji 2.0.0 Schindelin et al., 2012 https://fiji.sc/
Clustal Omega Madeira et al., 2019 https://www.ebi.ac.uk/Tools/msa/clustalo





For pulsed EdU (5-ethylnyl-20-desoxyuridine, Thermo Fisher Scientific) incorporation, cells were incubated for 20 minutes in medium
containing 10 mM EdU. The Click-iT EdU Alexa Fluor Imaging Kit (Thermo Fisher Scientific) was used for EdU detection.
siRNA and plasmid transfections
Transfections with siRNAs were performed for 72h, unless stated otherwise, with Ambion Silencer Select siRNA using Lipofectamine
RNAi/MAX (Thermo Fisher Scientific). For individual transfections the siRNAs were used at a final concentration of 25nM. When mul-
tiple siRNAs were combined, the final concentration was kept constant in all samples of an experiment. The following Ambion
Silencer Select siRNAs were used: TRIP12 (s17808, s17809, s17810), PARP1 (s1098), DTX1 (s4355, s4356), DTX2 (s41519,
s223231), DTX4 (s23319, s23321), HUWE1 (s19596, s19597), RNF146 (s37821, s37822), PARG (s16158). Negative Silencer Select
control Neg1 from Ambion was used as a non-targeting control (siControl). Plasmid transfections were performed using Lipofect-
amine 3000 (Thermo Fisher Scientific) or Fugene HD (Promega) according to the manufacturer’s recommendations. Calcium phos-
phate transfection was used for HEK293T cells. Unless stated otherwise, cells were analyzed 24h after transfection.
Antibodies
GFP (rabbit, TP401, Torrey Pines Biolabs; 1:1000 for WB, 1 mg for IP), TRIP12 (rabbit, A301-814A, Bethyl; 1:500 for WB, 1 mg for IP),
Tubulin (mouse, T6199, Sigma; 1:5000 for WB), PARP1 (rabbit, ab227244, Abcam; 1:500 for IF, 1:1000 for WB), PARP1 (H-250) (rab-
bit, sc-7150, Santa Cruz; 1:500 for IF, 1:1000 forWB), PARP2 (rabbit, 39743, ActiveMotif, 1:500 forWB), c-Myc (mouse, sc-40, Santa
Cruz; 1:500 for WB), Poly(ADP-ribose) (rabbit, ALX-210-890A-0100, Enzo; 1:1000 for IF, 1:2000 for WB), gH2AX (mouse, 613402,
BiolLegend, 1:1000 for IF), gH2AX (rabbit, 9718, Cell Signaling, 1:1000 for IF), AIF (rabbit, sc-5586, Santa Cruz, 1:500 for IF),
FLAG (mouse, F3165, Sigma; 1:1000 WB), Ub P4D1 (mouse, sc-8017, Santa Cruz; 1:1000 for WB), HA.11 (mouse, 901513, Bio-
Legend; 1:1000 for WB), H3 (rabbit, ab1791, Abcam; 1:5000 for WB), 53BP1 (mouse, MAB3802 Merk Millipore; 1:1000 for IF),
RAD51 (rabbit, 70-002, BioAcademia; 1:1000 for IF), XRCC1 (mouse, H00007515-B01P, Novus Biologicals; 1:500 for IF), MDC1 (rab-
bit, ab11171, Abcam, 1:1000 for IF), RPA70 (rabbit, ab79398, Abcam, IF 1:500 for IF), RNF168 (rabbit, 1:2000 for WB, kindly provided
by Daniel Durocher).
Immunostaining
For standard immunofluorescence staining, high-content microscopy and QIBC analyses, cells were seeded on sterile 12 mm glass
coverslips and allowed to proliferate until they reached a cell density of 70%–90%. Cells were then fixed in 3% formaldehyde for
15 minutes at room temperature, washed once in PBS, permeabilized for 5 minutes at room temperature in 0.2% Triton X-100
(Sigma-Aldrich) in PBS, washed twice in PBS and incubated in blocking solution (filtered DMEM containing 10% FBS and 0.02%
Sodium Azide) for 15 minutes at room temperature. When the staining was combined with an EdU Click-iT reaction, this reaction
was performed prior the incubation with primary antibody according to manufacturer’s recommendations (Thermo Fisher Scientific).
Where indicated, cells were pre-extracted in 0.2% Triton X-100 in PBS for two minutes on ice prior to formaldehyde fixation. To pre-
serve cellular PAR levels during the fixation step, the formaldehyde solution was supplemented with PARPi and PARGi to a final con-
centration of 10 mM each (Figures 5A, S2A, and S2B). All primary antibodies were diluted in blocking solution and incubated for 2h at
room temperature. Secondary antibodies (Alexa Fluor 488, 568, 647 anti-mouse and anti-rabbit IgG from Thermo Fischer Scientific)
were diluted 1:500 in blocking solution and incubated at room temperature for 1h. Cells were washed once with PBS and incubated
for 10 minutes with 4’,6-Diamidino-2-Phenylindole Dihydrochloride (DAPI, 0.5 mg/ml) in PBS at room temperature. Following three
washing steps in PBS, coverslips were briefly washed with distilled water and mounted on 5 ml Mowiol-based mounting media (Mo-
wiol 4.88 (Calbiochem) in Glycerol/TRIS).
High-content microscopy and quantitative image-based cytometry (QIBC)
Automated multichannel wide-field microscopy for high-content imaging and quantitative image-based cytometry (QIBC) was per-
formed using the Olympus ScanR System as described previously (Kilic et al., 2019; Teloni et al., 2019). Images were analyzed with
the inbuilt Olympus ScanR Image Analysis Software Version 3.0.1, a dynamic background correction was applied, and nuclei segmen-
tation was performed using an integrated intensity-based object detection module based on the DAPI signal. All downstream analyses
were focused on properly detected nuclei containing a 2C-4C DNA content as measured by total and mean DAPI intensities. Fluores-
cence intensities were quantified and are depicted as arbitrary units. Color-coded scatterplots of asynchronous cell populations were
generated with Spotfire data visualization software (TIBCO) and GraphPad Prism 8.0 was used for depicting data as violin plots. Within
one experiment, similar cell numbers were compared for the different conditions. For visualizing discrete data in scatterplots, mild jitter-
ing (random displacement of data points along discrete data axes) was applied in order to demerge overlapping data points. Represen-
tative scatterplots and quantifications of independent experiments, typically containing several thousand cells each, are shown.
Laser micro-irradiation
Cells were grown on 12 mm coverslips and pre-sensitized with 10 mM 50-bromo-2-deoxyuridine (BrdU) for 24 hours prior to laser mi-
cro-irradiation with a pulsed UV-A laser. Laser tracks were visualized on a Leica DMI 6000 inverted microscope using an HCX Plan
APO DIC 63x oil objective (1.4-0.6 NA) and analyzed using Fiji.




RNA extraction, reverse transcription and quantitative PCR
RNA was purified with TRIzol reagent (Life Technologies), primed with random hexamers (11034731001, Roche) and reverse-tran-
scribed to cDNA using aMultiScribe Reverse Transcriptase (4311235, Thermo Fisher). Quantitative PCR (qPCR) was performed with
KAPA SYBR FAST qPCR Kit (KAPA Biosystems) on a Rotor Gene Q system (QIAGEN). Samples were run in triplicates, normalized to
RPS12, and the results are depicted as relative fold changes. All primer sequences are provided in the Key Resources Table.
Plasmids and constructs
Cloning was done using chemically competent bacteria generated in-house, derived from Library EfficencyTM DH5aTM Competent
Cells (Thermo Fisher Scientific). Correct cloning, integration into target vectors andmutagenesis was confirmed by DNA sequencing.
Cloning of GFP-tagged TRIP12 plasmids
The TRIP12 cDNA was cloned into pAc-GFP1-C1 (Clontech) using the primers TRIP12 KpnI_to_pAc_fwd and TRIP12 XmaI_to_pA-
c_rev. The complete WWE domain (as encoded by TRIP12 transcript ENST 00000389044.8) was generated by insertion of a DNA
fragment encoding for the TRIP12 amino acid sequence AAHQVGEDEISLSTLGRVYTIDFNSMQ, synthesized by Integrated DNA
technologies (IDT) with 50-PvuI and 30-NruI restriction sites. The primers WWE domain PvuI_to_pAc_fwr and WWE domain NruI_to_
pAc_rev were used to insert the fragment. The amino acid substitutions C2034A and R869A were generated by site-directed muta-
genesis with the following primers: TRIP12 C2034A_fwr, TRIP12 C2034A_rev, TRIP12 R869A_fwr and TRIP12 R869A_rev.
The siRNA resistant versions of the pAc-GFP1-C1 TRIP12 constructs were generated by site-directed mutagenesis resulting in
silent mutations using the following primers: TRIP12_siRES_fwr and TRIP12_siRES_rev.
Cloning of FLAG-tagged TRIP12 plasmids
The pcDNA 3.1 FLAG TRIP12 WT, C2034A and R869A plasmids were generated by Gibson assembly with the following homology
primers TRIP12 GA_to_pcDNA_fwr and TRIP12 GA_to_pcDNA_rev. pcDNA 3.1 FLAG vector was linearized with Phusion High-Fidel-
ity polymerase using primers pcDNA 3.1 FLAG_lin_fwr and pcDNA 3.1 FLAG_lin_rev.
Cloning of GST-TRIP12 WWE plasmids
GST-TRIP12 WWE plasmids were generated by PCR amplification of the WWE domain from full-length WT and R869A GFP-TRIP12
plasmids using primers WWE domain EcoRI_to_pGEX_fwr and WWE domain EagI_to_pGEX_rev.
The target vector pGEX 6P-1 was linearized with EcoRI and EagI for 2h at 37C, followed by dephosphorylation with calf intestinal
phosphatase (CIP, NEB) for 1 hour at 37C. The PCR amplified TRIP12WWE domain encoding sequences were digested with EcoRI
and EagI for 2h at 37C, followed by gel purification and ligation using the Rapid Ligation Kit (Roche).
PARP1 and ubiquitin expression plasmids
The pcDNA-Myc-PARP1 WT, pcDNA-Myc-PARP1 E998K, and the pCMV-FLAG-PARP1 plasmids were kindly provided by Michael
Hottiger. The pcDNA-HA-Ubiquitin plasmid was kindly provided by Lorenza Penengo.
TRIP12 purification from HEK293T cells
HEK293T cells were transfected with plasmids encoding FLAG-TRIP12 WT or the point mutants R869A or C2034A. Cells were lysed
in TNE buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0,1% Igepal CA630, 1 mM EDTA) supplemented with 2 mM MgCl2, cOmplete
inhibitor cocktail (Roche), phosphoSTOP (Roche) and 25 U/ml benzonase. One milligram of protein lysates was immunoprecipitated
using proteinG-Sepharose (GEHeltcare) coupled to 1 mg of anti-FLAG antibody for 3 hours at 4C. After four washeswith IP buffer the
beads were first equilibrated in TE buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl) supplemented with cOmplete inhibitor cocktail
(Roche), 1 mM PMSF, and then re-suspended in 5 volumes of TE buffer with 0.3 mg/ml FLAG peptide (3x FLAG peptide, Sigma)
for 1 hour at 4C at low rpm. Samples were then centrifuged at 100 x g for two minutes and the supernatant containing the eluted
protein was stored at 80C.
In vitro ADP-ribosylation assay with recombinant proteins
To obtain auto-PARylated PARP1, human recombinant His-tagged PARP1 was incubated in reaction buffer RB (50 mM Tris-HCl pH
8.0, 4 mMMgCl2, 150 mM NaCl, 1x cOmplete inhibitor cocktail) supplemented with 20 mM - 200 mM of NAD
+ and 200 nM of double-
stranded annealed 40 bp long oligomer (40bp long oligomer_fwr and 40bp long oligomer_rev) for 15 minutes at 37C. Auto-PARy-
lation was stopped by addition of Olaparib to a final concentration of 10 mM.
In vitro ubiquitylation
Auto-PARylated PARP1 was bound to histidine beads (ProBond) for 45 minutes at 4C. The beads were then equilibrated in reaction
buffer (25 mM Tris-HCl pH 7.4, 100 mM NaCl) and equally distributed in reaction tubes. 20 ml of FLAG-TRIP12 WT or mutants were
incubated with 0.3 mg human recombinant E1 Ubiquitin-activating enzyme (UBE1, E-305-025, Boston Biochem), 0.3 mg of human
recombinant UBE2L3 (E2-640, Boston Biochem), and 1 mg of purified ubiquitin in 25 mM Tris-HCl pH 7.4, 100 mM NaCl at 30C
for 2h and 30 minutes at low rpm. Energy regeneration system was used to recycle ATP in the reaction (B-10, Boston Biochem).




The supernatant was then collected by 100 x g centrifugation for 2 minutes and then boiled at 95C for 5 minutes after the addition of
10x SDS-PAGE loading buffer. The remaining beads, containing the bound PARP1, were then boiled at 95C for 5 minutes after the
addition of 10x SDS-PAGE loading buffer. Supernatant and beads were run on two separate gels (Bolt 4%–12% Bis-Tris Plus,
NW04122, Thermo Fisher Scientific) and transferred onto polyvinylidene difluoride (PVDF) membranes (GE Healthcare). Membranes
were denatured using a solution containing 6 M guanidine hydrochloride, 20 mM Tris-HCl (pH 7.4), 1 mM PMSF, and 5 mM b-mer-
captoethanol for 30 min at 4C. After extensive washing in Tris-buffered saline (TBS), membranes were blocked in TBS buffer con-
taining bovine serum albumin (BSA) (5%) overnight and then incubated with anti-Ub P4D1 antibody (Santa Cruz) for 1 h or with the
indicated antibodies. For in vitro ubiquitylation assays to monitor TRIP12 activity in absence or presence of purified PAR chains, 20 ml
of purified FLAG-TRIP12 WT or R869A mutant were incubated with 0.3 mg E1, 0.3 mg E2, 1 mg of ubiquitin, and purified PAR (4336-
100-01, TREVIGEN) at 0, 0.2, or 1 mMfinal concentration in 25mMTris-HCl pH 7.4, 100mMNaCl at 30C for 2h and 30minutes at low
rpm. Energy regeneration system (B-10, Boston Biochem) was used in all reactions to recycle ATP. The reactions were stopped by
adding 10x SDS-PAGE loading buffer and samples were boiled for 5 minutes at 95C. Proteins were separated by SDS-PAGE (Bolt
4%–12% Bis-Tris Plus, NW04122, Thermo Fisher Scientific) and transferred onto polyvinylidene difluoride (PVDF) membranes (GE
Healthcare). Membranes were denatured using a solution containing 6 M guanidine hydrochloride, 20 mM Tris-HCl (pH 7.4), 1 mM
PMSF, and 5 mM b-mercaptoethanol for 30 min at 4C. After extensive washing in Tris-buffered saline (TBS), membranes were
blocked in TBS buffer containing bovine serum albumin (BSA) (5%) overnight and then incubated with anti-Ub P4D1 antibody (Santa
Cruz) for 1 h.
GST pull-down assays
Expression of recombinant GST-fusion proteins was performed in BL21 (DE3) cells from pGEX-6P-1 encoding GST, GST-TRIP12-
WWEWT or GST-TRIP12-WWE R869A. 4 mL of bacterial pre-culture from a single colony was inoculated into 400 mL of LB medium
with 100 mg/ml ampicillin and grown at 37C and 230 rpm until reaching OD600 of 0.6. The expression was induced with 0.5mM IPTG
for 2 hours at 37C and 230 rpm. Bacteria were harvested by centrifugation at 50000 x g for 20 min and resuspended in 20 mL binding
buffer (50 mM Tris pH 7.4, 200mMNaCl, 0.05%NP-40, 1 mMEDTA, 1 mMDTT, 10% glycerol, 1 mM PMSF, pepstatin, bestatin, and
leupeptin 1 mg/ml each) followed by cell lysis by two passages through a French press. The supernatant was recovered by centrifu-
gation at 25’000 x g for 30 min. The supernatant was loaded onto a pre-equilibrated 1 mL GSTrap HF column (GE Healthcare Life
Sciences) and washed with 10 column volumes of binding buffer. Bound proteins were eluted with 10 column volumes of elution
buffer (50mMTris pH 7.4, 15 0mMNaCl, 0.05%NP-40, 1mMEDTA, 1mMDTT, 10%glycerol, 40mMglutathione, and 1 tablet cOm-
plete protease inhibitor tablet (Roche) per 50 mL buffer). Eluted fractions were analyzed by 10% SDS-PAGE. Peak fractions with the
highest concentration were pooled and dialyzed against dialysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT,
20% glycerol) and the protein concentration was determined by Bradford assay.
For in vitro interactions with purified proteins, 2 mg of human recombinant PARP1 was incubated in reaction buffer RB (50mM Tris-
HCl pH 8.0, 4 mM MgCl2, 150 mM NaCl, 1x cOmplete inhibitor cocktail) supplemented with 20 mM - 200 mM NAD
+ and 200 nM of
annealed double-strand break-mimicking oligomer (40bp long oligomer_fwr and 40bp long oligomer_rev) for 15 minutes at 37C.
Meanwhile, purified GST, GST-TRIP12 WWE WT and GST-TRIP12 WWE R869A (4 mg each) were bound to glutathione Sepharose
beads (GE Healtcare) in PBS for 45 minutes at 4C. The beads were then equilibrated in TNE buffer (50 mM Tris-HCl pH 8.0, 150 mM
NaCl, 0,1% Igepal CA630, 1mMEDTA) supplemented with cOmplete inhibitor cocktail (Roche) and phosphoSTOP (Roche) and incu-
bated with unmodified or auto-PARylated PARP1 for 2 hours at 4C. The beads were collected by centrifugation, washed four times
with TNE buffer and eluted by boiling in 10x SDS-PAGE sample buffer. Samples were run on SDS-PAGE and subjected to
immunoblotting.
For in vitro interactions with whole cell extracts, HeLa cells were transfected with siPARG and treated with 1 mM H2O2 for 15 mi-
nutes. Cells were collected after two washes with cold PBS and lysates were prepared with TNE buffer (50 mM Tris-HCl pH 8.0,
150 mMNaCl, 0,1% Igepal CA630, 1 mMEDTA) supplemented with cOmplete inhibitor cocktail (Roche) and phosphoSTOP (Roche).
5 mg of GST, GST-TRIP12 WWE WT and GST-TRIP12 WWE R869A were bound to glutathione Sepharose beads (GE Healtcare) in
PBS supplemented with 0.05% Igepal for 1 hour at 4C. The GST-proteins were thenwashed twice in PBS and combined with 500 mg
of HeLa cell lysates for 2 hours at 4C. The beadswere collected by centrifugation, washed three timeswith PBS and eluted by boiling
in 10x SDS-PAGE sample buffer.
In vivo ubiquitylation
HEK293T or U-2 OS cells transfected with the indicated plasmids and siRNAs were washed twice with cold PBS and directly lysed on
ice with RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Igepal CA630, 0.1% SDS, 0.1% Na-deoxycholic acid), supplemented
with 2mMMgCl2, cOmplete inhibitor cocktail (Roche), phosphoSTOP (Roche), 25 U/ml benzonase, 1mMphenylmethylsulfonylfluoride
(PMSF), and 10mMN-ethylmaleimide (NEM). Lysateswere incubated for 5minutes at room temperature and then centrifuged at 15’000
x g for 15minutes. 500 mg of lysates were incubated with protein G-Sepharose (GEHealtcare) coupled to 1 mg of anti-Myc or anti-FLAG
antibody for 3 hours at 4C. Beads were collected by centrifugation, washed four times with RIPA buffer and eluted by boiling in 10x
SDS-PAGE sample buffer. Samples were subjected to SDS-PAGE for immunoblotting. For PARP1 ubiquitylation upon overexpression
of TRIP12 wild-type or mutant and upon TRIP12 depletion, IP samples were adjusted based on input levels of PARP1 to correct for the
effect of TRIP12 on PARP1 abundance and allow comparisons between samples containing similar PARP1 amounts.





HEK293T cells were treated as indicated and the cells were washed twice with cold PBS and directly lysed on ice in 500 ml of TNE
buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0,1% Igepal CA630, 1 mM EDTA) supplemented with 1 mM DTT, 2 mMMgCl2, cOm-
plete inhibitor cocktail (Roche), phosphoSTOP (Roche) and 25 U/ml benzonase. Cell lysates were incubated for 5 minutes at room
temperature and then centrifuged at 15’000 x g for 15 minutes. 800 mg of lysates were then incubated with 1 mg of rabbit anti-TRIP12
antibody (A301-814A, Bethyl) for 3 hours at 4C. Protein G-Sepharose beads (20 ml slurry, 17-0618-01, GE Healthcare) were added
for an additional hour. Beads were then collected by centrifugation, washed four times with TNE buffer and eluted by boiling in 10x
SDS-PAGE sample buffer. Samples were run on SDS-PAGE and subjected to immunoblotting.
HEK293T cells were transfected as indicated and cells were washed twice with cold PBS and directly lysed on ice in 500 ml TNE
buffer (50 mM Tris-HCl pH 8.0, 150 mMNaCl, 0,1% Igepal CA630, 1 mM EDTA) supplemented with 2 mMMgCl2, cOmplete inhibitor
cocktail (Roche), phosphoSTOP (Roche) and 25 U/ml benzonase. Cell lysates were incubated for 5 minutes at room temperature and
then centrifuged at 15’000 x g for 15 minutes. 500 mg of lysate was then incubated with protein G-Sepharose coupled to 1 ml of anti-
FLAGor anti-GFP antibody for 12 hours at 4C. Beadswere collected by centrifugation, washed four timeswith TNE buffer and eluted
by boiling in 10x SDS-PAGE sample buffer. Samples were subjected to SDS-PAGE for immunoblotting. For PARP1 interactions upon
loss or gain of TRIP12 function, IP samples were adjusted based on PARP1 input signals to correct for the effect of TRIP12 on PARP1
abundance and allow comparisons between samples containing similar PARP1 amounts.
Chromatin fractionation
Cell pellets were collected by scraping the cells in 1x PBS supplemented with 1x protease inhibitor cocktail (cOmplete, Roche) and
split in two equal fractions: (A) for the total proteome, cells were resuspended in 1x MNase buffer (0.3 M Sucrose, 50 mM Tris pH 7.5,
30 mM KCl, 7.5 mM NaCl, 4 mM MgCl2, 1 mM CaCl2, 0.125% NP-40, 0.25% Na-Deoxycholate) supplemented with 1x protease in-
hibitor cocktail and 10UofMNase for every 5million cells. Cells were incubated for 30min at 37C, boiled in 1x SDS-loading buffer for
5 min, spun down at 16’000 x g for 5 min and the supernatant was collected for immunochemical assays. (B) For chromatin-bound
and soluble fractions, cells were resuspended in chromatin extraction buffer (10mMHEPES pH 7.6, 3mMMgCl2, 0.5%Triton X-100,
1 mM DTT) supplemented with 1x protease inhibitor cocktail. Cells were rotated for 30 min at room temperature and spun down at
1’300 x g for 10min at 4C. The pellet was kept and the supernatant was centrifuged at 16’000 x g for 5min at 4Cand collected again
(soluble fraction). The supernatant was boiled in 1x SDS-loading buffer for 5 min, spun down at 16’000 x g for 5 min and used for
immunochemical assays. The pellet of the chromatin extraction step (chromatin-bound fraction) was resuspended in MNase buffer
supplemented with 1x protease inhibitor cocktail and 10 U of MNase for every 5million cells. Cells were incubated for 30min at 37C,
boiled in 1x SDS-loading buffer for 5 min, spun down at 16’000 x g for 5 min and the supernatant was collected for immunochemical
assays. Protein amounts were quantified using the standard Bradford method before addition of the SDS-PAGE loading buffer.
Immunoblotting
Proteins were separated by standard SDS-PAGE and transferred onto PVDF membranes. To reduce auto-PARylation of PARP1
interfering with PARP1 abundance measurements by western blot, cell extracts were treated with purified PARG to degrade PAR
for 15 minutes at 37C after cell lysis (Figures 1D, 1E, 4C, 4D, 4F, 1F, 1G, 1H, and 3B). Membranes were blocked with 5% milk in
PBS-T (PBS + 0.1% Tween-20) for one hour at room temperature and incubated with primary antibodies over night at 4C. Mem-
branes were then washed three times with PBS-T and incubated with HRP-conjugated secondary antibodies for one hour at
room temperature, washed again three timeswith PBS-T, and protein signals were detected using ECLTMWestern Blotting Detection
Reagent (AmershamTM).
Clonogenic survival assay
Cells transfected with the indicated siRNAs or induced by addition of doxycycline were seeded at single cell density and exposed to
PARPi at the indicated final concentration. All conditions were performed in triplicates. Cells were then incubated for 10 days and the
number of colonies with more than 50 cells was counted after staining with crystal violet (0.5% crystal violet in 20% ethanol). Graph-
Pad Prism 8.0 was used to display clonogenic survival data.
Cancer genomics analyses
A total of 102 breast cancer samples and 145 ovarian cancer samples, for which both transcriptomics and proteomics data are pub-
licly available, were analyzed for correlations between transcript and protein levels (Goncalves et al., 2017). Proteomics data were
generated by the NCI/NIH Clinical Proteomic Tumor Analysis Consortium (CPTAC) (Edwards et al., 2015; Ellis et al., 2013). Transcrip-
tomics data were generated by the TCGAResearch Network: https://www.cancer.gov/tcga (Grossman et al., 2016). As copy number
loss (CNL) is a primary confounding factor for protein expression, samples with PARP1 CNL were excluded from the analyses. For
transcriptomics analyses, raw TRIP12 and PARP1 transcript signals were normalized to the total RNA signals per sample. For pro-
teomics analyses, the unshared log ratio was used as raw value. The ovarian cancer proteome data were generated in two batches,
which were merged with z-score normalization within each batch. For BRCA1/2 mutation records, we matched rsID from reported
somatic mutations with the Ensembl SNP database (retrieved from R BioMart library, Ensembl Variation 99) with missense variants
and labeled the samples as BRCA mutated if either BRCA1 or BRCA2 contained such a mutation. Samples without such mutations




were considered as BRCA wild-type (WT). To determine the effect of TRIP12 transcript levels on PARP1 protein levels, a two-step
linear regression was used: First, a linear model was built with PARP1 protein levels as response variable and PARP1 transcript levels
as predictor. The residual PARP1 protein levels from the first model were then used in the second linear model for TRIP12 transcript
association.
Protein sequence alignments
Multiple sequence alignment of WWE domains was performed analogous to previous work (Wang et al., 2012) using Clustal Omega:
https://www.ebi.ac.uk/Tools/msa/clustalo/
QUANTIFICATION AND STATISTICAL ANALYSIS
For QIBC analysis, between 9 and 20 images per condition, depending on themicroscope objective used and the cell confluence (i.e.,
9 images with a 10x objective and 20 images with a 20x objective) were acquired in an unbiased fashion from asynchronous cell pop-
ulations grown on glass coverslips. Typically, between 1000 and 5000 cells per condition were analyzed, and representative single
cell data of cell cohorts of comparable size are shown as one- or two-dimensional cell cycle-resolved scatterplots. Fluorescence in-
tensities were quantified and are depicted as arbitrary units. Color-coded scatterplots of asynchronous cell populations were gener-
ated with Spotfire data visualization software (TIBCO). Within one experiment, similar cell numbers were compared for the different
conditions. For visualizing discrete data in scatterplots, mild jittering (random displacement of data points along discrete data axes)
was applied in order to demerge overlapping data points. Representative scatterplots and quantifications of independent experi-
ments are shown. GraphPad Prism 8.0 was used for depicting data as violin plots and unpaired t test was used for statistical analysis.
qPCRs to confirm knockdown efficiencies were performed in technical triplicates with results depicted as means ± SD. Fiji was used
for quantification of Western Blot band intensities. For laser micro-irradiation, the average pixel intensity of laser tracks was
measured within the locally irradiated area (Idamage), in the nucleoplasm outside the locally irradiated area (Inucleoplasm) and in a region
not containing cells in the same field of view (Ibackground). The level of protein accumulation relative to the protein level in the nucle-
oplasm was calculated as follows: (Idamage - Ibackground)/(Inucleoplasm - Ibackground). The data are presented as means ± SD obtained
from 15 to 30 cells per condition. GraphPad Prism 8.0 was used to display clonogenic survival data, represented as means ± SD.
****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; pR 0.05 was considered not significant.
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